Status:
RECRUITING
TumorGlow Intraoperative Molecular Imaging (IMI)
Lead Sponsor:
University of Pennsylvania
Conditions:
Tumor, Solid
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This is a Phase 1/2 study in patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment who ar...
Eligibility Criteria
Inclusion
- Adult patients 18 years of age or older.
- Patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment.
- Good operative candidate as determined by the treating physician and/or multidisciplinary team.
- Subject capable of giving informed consent.
Exclusion
- Subject unable to participate in the consent process.
- Vulnerable population including pregnant women, prisoners, and children.
- History of uncontrolled hypertension (e.g., history of an ER admission for hypertensive crisis or ≥ 3 blood pressure medications)
- Patients with a self-reported history of iodide allergies.
Key Trial Info
Start Date :
August 14 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 14 2026
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04723810
Start Date
August 14 2024
End Date
January 14 2026
Last Update
October 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104